FDA Approves Lembaz: First Therapy Shown to Extend Survival in Infantile-Onset NPC
Niemann-Pick disease type C(NPC)is a rare inherited lysosomal storage disorder,usually caused by mutations in NPC1 or NPC2.Faulty cholesterol trafficking lets lipids accumulate inside cells—especially in the brain.When neurological symptoms appear before age 6,the disease progresses fast and carries a high risk of early death.Until now,treatment mostly meant managing symptoms.
On November 17,2026,the FDA approved Lembaz(adrabetadex)injectionfor patients aged 6 years and older at symptom onset,weighing at least 7 kg.It is the first approved therapy shown to reduce the risk of deathin this population.
Lembaz is a cyclodextrin-based drug given intrathecally every two weeks by trained clinicians.Rather than only blunting symptoms,it targets the root defect:helping trapped cholesterol move correctly inside cells.
The approval rests on three clinical studies plus an expanded-access program,covering 36 infantile-onset patients.Versus a matched external control,Lembaz cut the risk of death by 55%.Median survival was 8.5 yearswith treatment vs.4.9 yearsin the control group.The survival benefit was seen whether or not patients also took miglustat.
The trade-off is real.Lembaz carries a boxed warning for hearing loss,including permanent hearing impairment.Baseline and ongoing audiologic monitoring are required,with dosing adjusted by hearing results.Other common side effects include balance and coordination problems,fatigue,vomiting,back pain,headache,fever,diarrhea,nausea,and cough.
Lembaz moves NPC care from"managing decline"toward"buying time."But the evidence uses external controls and a small sample—how the benefit and the hearing risk balance out will keep being tested in the real world.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)